Home > Pulmonology > ATS 2019 > Critical Care Medicine > SPICE III Trial: Early Sedation with Dexmedetomidine in Critically Ill Patients

SPICE III Trial: Early Sedation with Dexmedetomidine in Critically Ill Patients

Presented By
Prof. Yahya Shehabi, Monash Health, Australia
Conference
ATS 2019
Trial
SPICE III

Dexmedetomidine was not superior to propofol or midazolam for intensive care unit (ICU) sedation, led to more bradycardia and hypotension, and often required additional sedation. Prof. Yahya Shehabi (Monash Health, Australia) presented these data, which were simultaneously published in the New England Journal of Medicine [1,2].

Sedation of critically ill patients on ventilation is a part of their medical care, though the best choice of sedative is not definitively known. Dexmedetomidine, an adrenergic agonist of the alpha-2 receptor, may provide benefit as a sedative compared with traditional propofol or midazolam agents. Prior studies have shown an association between dexmedetomidine use and shorter time to extubation, reduced delirium, and lower mortality compared with other sedatives. The SPICE III trial (Sedation Practice in Intensive Care Evaluation) evaluated dexmedetomidine vs traditional...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on